Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
Although recent clinical trials targeting amyloid-β in Alzheimer’s disease have shown promising results, there is increasing evidence suggesting that understanding alternative disease pathways that interact with amyloid-β metabolism and amyloid pathology might be important to halt the clinical deterioration. In particular, there is evidence supporting a critical role of astroglial activation and astrocytosis in Alzheimer’s disease. However, so far, no studies have assessed whether astrocytosis is independently related to either amyloid-β or tau pathology in vivo. To address this question, we determined the levels of the astrocytic marker GFAP in plasma and CSF of 217 amyloid-β-negative cognitively unimpaired individuals, 71 amyloid-β-positive cognitively unimpaired individuals, 78 amyloid-β-positive cognitively impaired individuals, 63 amyloid-β-negative cognitively impaired individuals and 75 patients with a non-Alzheimer’s disease neurodegenerative disorder from the Swedish BioFINDER-2 study. Participants underwent longitudinal amyloid-β (18F-flutemetamol) and tau (18F-RO948) PET as well as cognitive testing. We found that plasma GFAP concentration was significantly increased in all amyloid-β-positive groups compared with participants without amyloid-β pathology (P < 0.01). In addition, there were significant associations between plasma GFAP with higher amyloid-β-PET signal in all amyloid-β-positive groups, but also in cognitively normal individuals with normal amyloid-β values (P < 0.001), which remained significant after controlling for tau-PET signal. Furthermore, plasma GFAP could predict amyloid-β-PET positivity with an area under the curve of 0.76, which was greater than the performance achieved by CSF GFAP (0.69) and other glial markers (CSF YKL-40: 0.64, soluble TREM2: 0.71). Although correlations were also observed between tau-PET and plasma GFAP, these were no longer significant after controlling for amyloid-β-PET. In contrast to plasma GFAP, CSF GFAP concentration was significantly increased in non-Alzheimer’s disease patients compared to other groups (P < 0.05) and correlated with amyloid-β-PET only in amyloid-β-positive cognitively impaired individuals (P = 0.005). Finally, plasma GFAP was associated with both longitudinal amyloid-β-PET and cognitive decline, and mediated the effect of amyloid-β-PET on tau-PET burden, suggesting that astrocytosis secondary to amyloid-β aggregation might promote tau accumulation. Altogether, these findings indicate that plasma GFAP is an early marker associated with brain amyloid-β pathology but not tau aggregation, even in cognitively normal individuals with a normal amyloid-β status. This suggests that plasma GFAP should be incorporated in current hypothetical models of Alzheimer’s disease pathogenesis and be used as a non-invasive and accessible tool to detect early astrocytosis secondary to amyloid-β pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, blood measures of p-tau181, p-tau217, p-tau231, glial fibrillary acid protein (GFAP), neurofilament light (NfL) and Aβ42/40 have been shown to change in preclinical AD and can discriminate this state from CU individuals with non-AD pathological changes1,3,6–13.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased GFAP, associated with astrogliosis, is a hallmark of and linked to pathological processes in Alzheimer’s disease, particularly amyloid build-up, and neuroinflammation [27].”
From Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer’s disease (2026) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For GFAP we observed more pronounced group differences in blood than in CSF, as has also been observed by other groups [33, 75].”
In the citing paper
“Elevated levels of GFAP in plasma and serum are associated with the degree and rate of neurodegeneration, Aβ positivity and cognitive decline in individuals with AD [27, 28].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 2×
“There is increasing evidence suggesting that the pathogenesis of Alzheimer’s disease is not restricted to amyloid-b plaques and tau tangles but also includes strong interactions with immunological mechanisms.(1) In line with this, astrocyte reactivity or astrocytosis is a well-known pathological process that is common…”
BackgroundMethodJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationPalmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · cited 5×
“Plasma and CSF samples were collected in the morning during the same visit, with participants non-fasting.(40) Blood was collected in six EDTA-plasma tubes and centrifuged (2000g, + 4 C for 10 min).”
MethodInfluentialSelf-citationSynergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90115-x · Cited by 940
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798
Self-citationTREM2 — a key player in microglial biology and Alzheimer disease
Ulland, T. K., & Colonna, M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0072-1 · Cited by 735 · cited 1×
“TREM2 variants seem to cause loss of function of TREM2 and reduce the ability of microglia to respond to toxic metabolites and clear them from the brain.(21) Although initial studies examining”
BackgroundSuárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522
Self-citation
Research works printed but not linked: 1
- Palmqvist, 2019, Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease, EMBO Mol Med, 11, e11170, 10.15252/emmm.201911170 · DOI · Paper page
Cited by
Items 101–200 of 660
Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer’s disease
Yang, Z., Sreenivasan, K. R., Strom, E. N. T., Osse, A. M. L., Pasia, L. G., Cosme, C. G., Mugosa, M. R. N., Chevalier, E. L., Ritter, A. R., Miller, J. B., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01340-4 · Cited by 49
O’Connor, A., Abel, E., Benedet, A. L., Poole, T., Ashton, N. J., Weston, P. S. J., Heslegrave, A., Ryan, N. S., Barker, S., Polke, J. M., et al. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329663 · Cited by 48
Self-citationSex Differences in Astrocyte Activity
Gozlan, E., Lewit-Cohen, Y., & Frenkel, D. (2024) · Cells · doi:10.3390/cells13201724 · Cited by 49
Serum GFAP – reference interval and preanalytical properties in Danish adults
Tybirk, L., Hviid, C. V. B., Knudsen, C. S., & Parkner, T. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0646 · Cited by 48
Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers
Cousins, K. A. Q., Shaw, L. M., Chen-Plotkin, A., Wolk, D. A., Van Deerlin, V. M., Lee, E. B., McMillan, C. T., Grossman, M., & Irwin, D. J. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.3265 · Cited by 45
Bouvier, D. S., Fixemer, S., Heurtaux, T., Jeannelle, F., Frauenknecht, K. B. M., & Mittelbronn, M. G. A. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.814889 · Cited by 47
Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis
Verde, F., Milone, I., Maranzano, A., Colombo, E., Torre, S., Solca, F., Doretti, A., Gentile, F., Manini, A., Bonetti, R., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51708 · Cited by 46
Jack, C. R., Wiste, H. J., Algeciras‐Schimnich, A., Weigand, S. D., Figdore, D. J., Lowe, V. J., Vemuri, P., Graff‐Radford, J., Ramanan, V. K., Knopman, D. S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13651 · Cited by 46
Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer’s disease
Guo, T., Li, A., Sun, P., He, Z., Cai, Y., Lan, G., Liu, L., Li, J., Yang, J., Zhu, Y., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00750-8 · Cited by 46
Bun, S., Ito, D., Tezuka, T., Kubota, M., Ueda, R., Takahata, K., Moriguchi, S., Kurose, S., Momota, Y., Suzuki, N., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01296-5 · Cited by 45
Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes
Meyer, S. D., Blujdea, E. R., Schaeverbeke, J. M., Reinartz, M., Luckett, E. S., Adamczuk, K., Laere, K. V., Dupont, P. J., Teunissen, C. E., Vandenberghe, R. R., et al. (2023) · Brain · doi:10.1093/brain/awad330 · Cited by 45
Self-citationBlood Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-Analysis
Holper, S., Loveland, P. M., Churilov, L. P., Italiano, D., Watson, R., & Yassi, N. (2024) · Neurology · doi:10.1212/wnl.0000000000209537 · Cited by 46
Ashton, N. J., Benedet, A. L., Molfetta, G. D., Pola, I., Anastasi, F., Fernández‐Lebrero, A., Puig‐Pijoan, A., Keshavan, A., Schott, J. M., Tan, K., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14621 · Cited by 46
Self-citationSchindler, P., Aktaş, O., Ringelstein, M., Wildemann, B., Jarius, S., Paul, F., & Ruprecht, K. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2148657 · Cited by 45
Fluid biomarkers for the diagnosis of neurodegenerative diseases
Luebke, M., Parulekar, M. S., & Thomas, F. P. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100062 · Cited by 45
Plasma biomarkers for prediction of Alzheimer’s disease neuropathologic change
Bermudez, C. L., Graff‐Radford, J., Syrjanen, J. A., Stricker, N. H., Algeciras‐Schimnich, A., Kouri, N., Kremers, W. K., Petersen, R. C., Jack, C. R., Knopman, D. S., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02594-w · Cited by 45
Livingston, N. R., Calsolaro, V., Hinz, R., Nowell, J., Raza, S., Gentleman, S., Tyacke, R. J., Myers, J., Venkataraman, A. V., Perneczky, R., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01429-y · Cited by 44
Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia
Ingannato, A., Bagnoli, S., Mazzeo, S., Giacomucci, G., Bessi, V., Ferrari, C., Sorbi, S., & Nacmias, B. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1375302 · Cited by 44
Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data
Karlsson, L., Vogel, J., Arvidsson, I., Åström, K., Strandberg, O., Seidlitz, J., Bethlehem, R. A. I., Stomrud, E., Ossenkoppele, R., Ashton, N. J., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.14600 · Cited by 43
Self-citationUchida, K. (2022) · Cells · doi:10.3390/cells11050919 · Cited by 43
Ketone bodies mediate alterations in brain energy metabolism and biomarkers of Alzheimer’s disease
Ramezani, M., Fernando, M. G., Eslick, S., Asih, P. R., Shadfar, S., Bandara, E. M. S., Hillebrandt, H., Meghwar, S., Shahriari, M., Chatterjee, P., et al. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1297984 · Cited by 43
Dark, H. E., Duggan, M. R., & Walker, K. A. (2024) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acae019 · Cited by 43
Wagemann, O., Liu, H., Wang, G., Shi, X., Bittner, T., Scelsi, M. A., Farlow, M. R., Clifford, D. B., Supnet, C. B., Santacruz, A. M., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.0991 · Cited by 43
Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET
Cogswell, P. M., Lundt, E. S., Therneau, T. M., Wiste, H. J., Graff‐Radford, J., Algeciras‐Schimnich, A., Lowe, V. J., Mielke, M. M., Schwarz, C. G., Senjem, M. L., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13539 · Cited by 42
A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings
Brum, W. S., Cullen, N. C., Therriault, J., Janelidze, S., Rahmouni, N., Stevenson, J., Servaes, S., Benedet, A. L., Zimmer, E. R., Stomrud, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46603-2 · Cited by 43
Self-citationLorenzini, L., Maranzano, A., Ingala, S., Collij, L. E., Tranfa, M., Blennow, K., Perri, C. D., Foley, C., Fox, N. C., Frisoni, G. B., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209801 · Cited by 42
Self-citationNeurodegeneration and inflammation crosstalk: Therapeutic targets and perspectives
Mohamed, W. M. Y., Kumar, J., Alghamdi, B. S. A., Wadan, A.-H. S., & Yamashita, T. (2022) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2022.12.003 · Cited by 42
Plasma GFAP as a prognostic biomarker of motor subtype in early Parkinson’s disease
Che, N.-N., Ou, R., Li, C., Zhang, L., Wei, Q., Wang, S., Jiang, Q., Yang, T., Xiao, Y., Lin, J., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00664-8 · Cited by 41
Vrillon, A., Bousiges, O., Götze, K., Demuynck, C., Muller, C., Ravier, A., Schorr, B., Philippi, N., Hourrègue, C., Cognat, E., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01502-y · Cited by 41
Reyes, R. E. R., Wilson, R. E., Langhough, R. E., Studer, R. L., Jonaitis, E. M., Oomens, J. E., Planalp, E. M., Bendlin, B. B., Chin, N. A., Asthana, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70166 · Cited by 41
Self-citationEarly microglial and astrocyte reactivity in preclinical Alzheimer's disease
Fernández‐Matarrubia, M., Barrero, A. V., Renuncio‐García, M., Aguilella, M., Lage, C., López‐García, S., Ocejo-Vinyals, J. G., Martínez‐Dubarbie, F., Molfetta, G. D., Pozueta‐Cantudo, A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70502 · Cited by 41
Self-citationChatterjee, P., Doré, V., Pedrini, S., Krishnadas, N., Thota, R. N., Bourgeat, P., Ikonomović, M. D., Rainey‐Smith, S. R., Burnham, S. C., Fowler, C. J., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220908 · Cited by 39
Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease
Cousins, K. A. Q., Irwin, D. J., Chen‐Plotkin, A. S., Shaw, L. M. J., Arezoumandan, S., Lee, E. B., Wolk, D. A., Weintraub, D. A., Spindler, M., Deik, A., et al. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51768 · Cited by 39
Gibson, L. L., Ruiz, C. A., Chong, J. R., Ballard, C. G., & Aarsland, D. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001173 · Cited by 38
Bandara, E. M. S., Asih, P. R., Pedrini, S., Hone, E., Fernando, W. M. A. D. B., & Martins, R. N. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05219-3 · Cited by 38
The rise of astrocytes: are they guardians or troublemakers of the brain disorder?
Kim, H. Y., Kim, S., Akaydin, A. N., Kim, S. S., Hyeon, S. J., Lee, J.-H., & Ryu, H. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01627-6 · Cited by 38
A new generation of AD biomarkers: 2019 to 2021
Hawksworth, J. I., Fernández, E., & Gevaert, K. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101654 · Cited by 37
PET imaging of reactive astrocytes in neurological disorders
Liu, Y., Jiang, H., Qin, X., Tian, M., & Zhang, H. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05640-5 · Cited by 37
Akel, S., Asztély, F., Banote, R. K., Axelsson, M., Zetterberg, H., & Zelano, J. (2023) · Epilepsia · doi:10.1111/epi.17713 · Cited by 37
Self-citationAlly, M., Sugarman, M. A., Zetterberg, H., Blennow, K., Ashton, N. J., Karikari, T. K., Aparicio, H. J., Frank, B. E., Tripodis, Y., Martin, B. M., et al. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12492 · Cited by 37
Self-citationBolsewig, K., Hok-A-Hin, Y. S., Sepe, F. N., Boonkamp, L., Jacobs, D., Bellomo, G., Paoletti, F. P., Vanmechelen, E., Teunissen, C. E., Parnetti, L., et al. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220318 · Cited by 36
“For GFAP we observed more pronounced group differences in blood than in CSF, as has also been observed by other groups [33, 75].”
Self-citationSalvadó, G., Milà-Alomà, M., Shekari, M., Ashton, N. J., Operto, G., Falcon, C., Cacciaglia, R., Minguillon, C., Fauria, K., Niñerola-Baizán, A., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05897-4 · Cited by 36
Self-citationBellelli, F., Angioni, D., Arosio, B., Vellas, B. J., & Barreto, P. D. S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102699 · Cited by 36
Zeng, X., Sehrawat, A., Lafferty, T. K., Chen, Y., Rawat, M., Kamboh, M. I., Villemagne, V. L., López, O. L., Cohen, A. D., & Karikari, T. K. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14535 · Cited by 36
Martínez‐Dubarbie, F., Guerra-Ruiz, A. R., López‐García, S., Lage, C., Fernández‐Matarrubia, M., Nevado-Cáceres, Á., Rivera‐Sánchez, M., Barrero, A. V., Pozueta‐Cantudo, A., García‐Martínez, M., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01719-5 · Cited by 37
Snellman, A., Ekblad, L. L., Ashton, N. J., Karikari, T. K., Lantero‐Rodriguez, J., Pietilä, E. A., Koivumäki, M., Helin, S., Karrasch, M., Zetterberg, H., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106175 · Cited by 36
Self-citationEdwards, N. C., Lao, P. J., Alshikho, M. J., Ericsson, O. M., Rizvi, B. M., Petersen, M. E., O’Bryant, S. E., Aguilar, L. F., Simoes, S., Mapstone, M. E., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae331 · Cited by 35
Self-citationSnellman, A., Ekblad, L. L., Tuisku, J., Koivumäki, M., Ashton, N. J., Lantero‐Rodriguez, J., Karikari, T. K., Helin, S., Bucci, M., Löyttyniemi, E., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01209-6 · Cited by 35
Self-citationNeuropathology, Neuroimaging, and Fluid Biomarkers in Alzheimer’s Disease
Colvee-Martin, H., Parra, J. R., Gonzalez, G. A., Barker, W., & Duara, R. (2024) · Diagnostics · doi:10.3390/diagnostics14070704 · Cited by 34
Mao, S., Teng, X., Li, Z., Zu, J., Zhang, T., Xu, C., & Cui, G. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148271 · Cited by 34
Honig, L. S., Kang, M. S., Lee, A., Reyes‐Dumeyer, D., Piriz, A. L., Soriano, B., Franco, Y., Coronado, Z. D., Recio, P., Mejía, D. R., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.8214 · Cited by 34
Yuan, W., Yuan, H., Li, R., Yong, R., Mitrović, I. Z., Lim, E. G., Duan, S., & Song, P. (2024) · Analytica Chimica Acta · doi:10.1016/j.aca.2024.342447 · Cited by 33
Álvarez-Sánchez, L., Peña-Bautista, C., Ferré-González, L., Balaguer, A., Baquero, M., Casanova-Estruch, B., & Cháfer-Pericás, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021226 · Cited by 32
Novel Biomarkers for Alzheimer’s Disease: Plasma Neurofilament Light and Cerebrospinal Fluid
Abukuri, D. N. (2024) · International Journal of Alzheimer s Disease · doi:10.1155/2024/6668159 · Cited by 32
González‐Escalante, A., Milà‐Alomà, M., Brum, W. S., Ashton, N. J., Ortiz-Romero, P. L., Shekari, M., del Campo, M., Anastasi, F., Quijano‐Rubio, C., Kollmorgen, G., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105741 · Cited by 33
Self-citationA critical appraisal of blood-based biomarkers for Alzheimer’s disease
Lista, S., Mapstone, M. E., Caraci, F., Emanuele, E., López‐Ortiz, S., Martín-Hernández, J., Triaca, V., Imbimbo, C., Gabelle, A., Mielke, M. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102290 · Cited by 32
Ravichandran, S., Snyder, P. J., Alber, J., Murchison, C., Chaby, L. E., Jeromin, A., & Arthur, E. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01668-5 · Cited by 31
Tsoy, E., Joie, R. L., VandeVrede, L. A., Rojas, J. C., Yballa, C., Chan, B., Lago, A. L., Rodriguez, A., Goode, C. A., Erlhoff, S. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13686 · Cited by 30
Differential roles of Alzheimer's disease plasma biomarkers in stepwise biomarker‐guided diagnostics
Jang, H., Shin, D., Yoo, H., Zetterberg, H., Blennow, K., González‐Ortiz, F., Ashton, N. J., Day, T. A., Lee, E. H., Yun, J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14526 · Cited by 29
Self-citationNeuroinflammation Biomarkers in the AT(N) Framework Across the Alzheimer's Disease Continuum
Bieger, A., Rocha, A., Bellaver, B., Machado, L., Da Ros, L., Borelli, W. V., Therriault, J., Macedo, A. C., Pascoal, T. A., Gauthier, S., et al. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.54 · Cited by 29
Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology
Sunde, A. L., Alsnes, I. V., Aarsland, D., Ashton, N. J., Tovar, D., Santis, G. D., Blennow, K., Zetterberg, H., & Kjosavik, S. R. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12439 · Cited by 29
Self-citationTang, H., & Harte, M. (2021) · Genes · doi:10.3390/genes12111753 · Cited by 28
Passive and receptor mediated brain delivery of an anti-GFAP nanobody
Meier, S. R., Sehlin, D., & Syvänen, S. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.04.002 · Cited by 28
Muir, R. T., Ismail, Z., Black, S. E., & Smith, E. E. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13510 · Cited by 29
Fang, T., Dai, Y., Hu, X., Xu, Y., & Qiao, J. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1320653 · Cited by 28
Chong, J. R., Chai, Y. L., Yam, T. Y. A., Hilal, S., Vrooman, H. A., Venketasubramanian, N., Blennow, K., Zetterberg, H., Ashton, N. J., Chen, C., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12576 · Cited by 27
Self-citationPlasma NfL and GFAP for predicting VCI and related brain changes in community and clinical cohorts
Raghavan, S., Graff‐Radford, J., Hofrenning, E. I., Fought, A. J., Reid, R. I., Kamykowski, M. G., Algeciras‐Schimnich, A., Windham, B. G., Knopman, D. S., Lowe, V. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70381 · Cited by 27
Jin, Z., Lu, Y., Tang, H., & Cui, H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70472 · Cited by 27
Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease
Gueorguieva, I., Willis, B. A., Chua, L., Chow, K. H., Ernest, C. S., Wang, J., Shcherbinin, S., Sims, J. R., & Chigutsa, E. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12404 · Cited by 27
Zou, Y., Wang, Y., Ma, X., Mu, D., Zhong, J., Ma, C., Mao, C., Yu, S., Gao, J., & Qiu, L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102485 · Cited by 26
From Amyloid to Synaptic Dysfunction: Biomarker-Driven Insights into Alzheimer’s Disease
Agnello, L., Gambino, C. M., Ciaccio, A. M., Cacciabaudo, F., Massa, D., Masucci, A., Tamburello, M., Vassallo, R., Midiri, M., Scazzone, C., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47080580 · Cited by 26
Uchida, Y., Nishimaki, K., Soldan, A., Pettigrew, C. A., Ho, S. G., Moghekar, A., Wang, M., Miller, M. I., Albert, M., & Oishi, K. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70544 · Cited by 26
3D models of neurodegeneration: implementation in drug discovery
Whitehouse, C. A., Corbett, N. J., & Brownlees, J. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.01.005 · Cited by 26
Asken, B. M., Tanner, J. A., Gaynor, L. S., VandeVrede, L. A., Mantyh, W. G., Casaletto, K. B., Staffaroni, A. M., Fonseca, C. S., Shankar, R. P., Grant, H. E., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01275-w · Cited by 26
Central autonomic network dysfunction and plasma Alzheimer’s disease biomarkers in older adults
Lohman, T., Kapoor, A., Engstrom, A. C., Shenasa, F., Alitin, J. P. M., Gaubert, A., Rodgers, K. E., Bradford, D. R., Mather, M., Han, S. D., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01486-9 · Cited by 26
Pathologic and clinical correlates of region-specific brain GFAP in Alzheimer’s disease
Phillips, J. M., Winfree, R. L., Seto, M., Schneider, J. A., Bennett, D. A., Dumitrescu, L. C., & Hohman, T. J. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02828-5 · Cited by 25
Graham, N., Blissitt, G., Zimmerman, K. A., Orton, L., Friedland, D., Coady, E., Laban, R., Veleva, E., Heslegrave, A., Zetterberg, H., et al. (2024) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-333777 · Cited by 25
Self-citationBiomarker treatment effects in two phase 3 trials of gantenerumab
Bittner, T., Tonietto, M., Klein, G., Belusov, A., Illiano, V. P., Voyle, N., Delmar, P., Scelsi, M. A., Gobbi, S., Silvestri, E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14414 · Cited by 25
Self-citationBlood Biomarkers for the Diagnosis of Neurodegenerative Dementia: A Systematic Review
Santos, F., Cabreira, V., Rocha, S., & Massano, J. (2023) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887221141651 · Cited by 24
Gopalakrishna, P. K., Nassir, C. M. N. C. M., Anandan, S., Hussan, F., Dandala, K. C. R., Sura, S., Jagadeesan, S., Moklas, M. A. M., Vishnumukkala, T., & Hein, Z. M. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01671-4 · Cited by 25
Liu, X., Yu, C., Yao, Y., Lai, H., Ye, X., Xu, J., Guo, J., Xiao, X., Chen, L., Huang, Z., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115120 · Cited by 24
Trieu, C., van Harten, A. C., Leeuwis, A. E., Exalto, L. G., Hooghiemstra, A. M., Verberk, I. M. W., Allaart, C. P., Rocca, H. B., Kappelle, L. J., van Oostenbrugge, R. J., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231096 · Cited by 24
Self-citationJiao, B., Ouyang, Z., Liu, Y., Zhang, C., Xu, T., Yang, Q., Zhang, S., Zhu, Y., Wan, M., Xiao, X., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01712-y · Cited by 23
Leng, K., Maze, M., & Chang, O. L. B. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1632947 · Cited by 23
Estimating the time course of biomarker changes in Alzheimer’s disease
Rakêt, L. L., Binette, A. P., Mattsson, N., Janelidze, S., Zetterberg, H., Ashton, N. J., Blennow, K., Stomrud, E., Palmqvist, S., & Hansson, O. (2025) · Brain · doi:10.1093/brain/awaf413 · Cited by 23
Self-citationSpotorno, N., Najac, C., Stomrud, E., Mattsson, N., Palmqvist, S., van Westen, D., Ronen, I., & Hansson, O. (2022) · Brain Communications · doi:10.1093/braincomms/fcac135 · Cited by 23
Self-citationPlasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy
Huang, S., Chen, S., Cui, M., Zhao, M., Shen, X., Guo, Y., Zhang, Y.-R., Zhang, W., Wang, H.-F., Huang, Y., et al. (2023) · Movement Disorders · doi:10.1002/mds.29339 · Cited by 23
Early Diagnosis of Alzheimer’s Disease: Moving Toward a Blood-Based Biomarkers Era
Tao, Q., Lin, R.-R., & Wu, Z. (2023) · Clinical Interventions in Aging · doi:10.2147/cia.s394821 · Cited by 23
Bonomi, C. G., Assogna, M., Donna, M. G. D., Bernocchi, F., Lucia, V. D., Nuccetelli, M., Fiorelli, D., Loizzo, S., Mercuri, N. B., Koch, G., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221010 · Cited by 23
Astrocyte Signature in Alzheimer’s Disease Continuum through a Multi-PET Tracer Imaging Perspective
Fontana, I. C., Scarpa, M., Malarte, M., Rocha, F. M., Ausellé‐Bosch, S., Blūma, M., Bucci, M., Chiotis, K., Kumar, A., & Nordberg, A. K. (2023) · Cells · doi:10.3390/cells12111469 · Cited by 23
Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic
Bucci, M., Blūma, M., Savitcheva, I., Ashton, N. J., Chiotis, K., Matton, A., Kivipelto, M., Molfetta, G. D., Blennow, K., Zetterberg, H., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02558-4 · Cited by 23
Self-citationKrix, S., Wilczynski, E., Falgàs, N., Sánchez‐Valle, R., Yoles, E., Nevo, U., Baruch, K., & Fröhlich, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1343900 · Cited by 23
Blūma, M., Chiotis, K., Bucci, M., Savitcheva, I., Matton, A., Kivipelto, M., Jeromin, A., Santis, G. D., Molfetta, G. D., Ashton, N. J., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105504 · Cited by 22
Self-citationWu, C., Liu, C., Fatima, H. A., Gatchel, J. R., Das, S., Kivisäkk, P., Arnold, S. E., & Dodge, H. H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70934 · Cited by 22
Plasma Alzheimer's biomarkers and brain amyloid in Hispanic and non‐Hispanic older adults
Asken, B. M., Wang, W., McFarland, K. N., Arias, F., Fiala, J. A., Vélez-Uribe, I., Mayrand, R. P., Sawada, L. O., Freytes, C. Y., Adeyosoye, M., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13456 · Cited by 22
Present and Future of Blood-Based Biomarkers of Alzheimer’s Disease: Beyond the Classics
Grigoli, M. M., Pelegrini, L. N. D. C., Whelan, R., & Cominetti, M. R. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148812 · Cited by 22
Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease
Cousins, K. A. Q., Phillips, J. S., Das, S. R., O’Brien, K. S., Tropea, T. F., Chen‐Plotkin, A. S., Shaw, L. M. J., Nasrallah, I. M., Mechanic-Hamilton, D. J., McMillan, C. T., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13777 · Cited by 22
Blood biomarkers in Down syndrome: Facilitating Alzheimer's disease detection and monitoring
Petersen, M. E., Aguilar, L. F., Head, E., Montoliu‐Gaya, L., Strydom, A., Pape, S. E., Fortea, J., Ashton, N. J., Udeh‐Momoh, C. T., O’Bryant, S. E., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14364 · Cited by 22
Self-citationAlzheimer’s disease: from early pathogenesis to novel therapeutic approaches
Prajapati, S. K., Pathak, A., & Samaiya, P. K. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01389-6 · Cited by 21
“However, a recent investigation discovered that all Aβ-positive groups had significantly higher plasma GFAP levels than those who did not have Aβ pathology (Pereira et al. 2021).”
InfluentialCerebral Amyloid Angiopathy and Downstream Alzheimer Disease Plasma Biomarkers
Kang, S. H., Lee, E. H., Kim, Y. J., Jang, H., Shin, D., Zetterberg, H., Blennow, K., González‐Ortiz, F., Ashton, N. J., Yun, J., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.8842 · Cited by 21
Self-citation
Metadata
- Authors
- Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., & Hansson, O.
- Affiliations
- Lund University (SE)
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden
- Amsterdam Neuroscience (NL)
- Sahlgrenska University Hospital (SE)
- King's College London (GB)
- Corresponding author
- Pereira, Joana B
- Hansson, Oskar
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-07-02
- Volume
- 144
- Issue
- 11
- Pages
- 3505-3516
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC8677538
- OpenAlex
- W3182927843
- Cited by
- 598
- References
- 61
- Citations by year
- 2026: 148 · 2025: 140 · 2024: 141 · 2023: 92 · 2022: 66 · 2021: 10
- FWCI
- 48.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Swedish Research Council (2016–00906, 2018–02052, #2018–02201, #2017–00915, #2018–02532)
- Knut and Alice Wallenberg foundation (2017–0383)
- Marianne and Marcus Wallenberg foundation (2015.0125)
- Strategic Research Area MultiPark
- Swedish Alzheimer Foundation (AF-939932, #AF-742881)
- Swedish Brain Foundation (FO2019-0326)
- The Parkinson foundation of Sweden (1280/20)
- Skåne University Hospital Foundation (2020-O000028)
- Regionalt Forskningsstöd (2020–0314)
- Swedish federal government (2018-Projekt0279)
- The Center for Medical Innovation (#20200695)
- Karolinska Institute
- Alzheimer Drug Discovery Foundation (#RDAPB-201809–2016615)
- Hjärnfonden, Sweden (#FO2017-0243)
- ALF (#ALFGBG-715986)
- European Union Joint Program for Neurodegenerative Disorders (JPND2019-466–236)
- European Research Council (#681712)
- Swedish State Support for Clinical Research (#ALFGBG-720931)
- UK Dementia Research Institute
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, tau pathology, astrocyte activation, astroglial activation, biomarkers, cerebrospinal fluid biomarkers, amyloid PET, tau PET, 18F-flutemetamol, cognitive impairment
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Female, Glial Fibrillary Acidic Protein, Humans, Male, Middle Aged, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.